Reports
Sale
Global Myelofibrosis Treatment Market Size, Share, Forecast: By Drug Type: Hydroxyurea, Immunomodulators, JAK Inhibitor, Others; By Treatment Type: Blood Transfusion, Chemotherapy, Androgen Therapy, Stem Cell/Bone Marrow Transplantation, Others; By End Use: Hospitals, Others; Regional Analysis; Competitive Landscape; 2024-2032
Global Myelofibrosis Treatment Market Outlook
The global myelofibrosis treatment market to be aided by the growth of the blood and bone marrow cancer treatment market. The global blood and bone marrow cancer treatment market is projected to grow at a CAGR of 7% in the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Awareness Regarding Chemotherapy to Aid the Myelofibrosis Treatment Industry
Based on treatment type, the chemotherapy segment holds a significant share in the global myelofibrosis treatment industry. The growth of the segment can be attributed to the easy availability of agents required for chemotherapy and the approval of Ruxolitinib (Jakafi) by the US Food and Drug Administration. It is a JAK1 and JAK2 inhibitor that targets overactive JAK pathway signalling, which plays a major role in the development of myelofibrosis. Currently, Ruxolitinib is the only FDA-approved chemotherapeutic agent for the treatment of myelofibrosis, which is driving the demand for this drug and aiding the growth of the segment.
North America to Significantly Contribute to the Myelofibrosis Treatment Industry Expansion
The global market for myelofibrosis treatment is expected to be dominated by the North America region. The demand is growing in the region due to the availability of advanced healthcare facilities and increased awareness regarding the treatment of cancer. The favourable government initiatives and the growing number of clinical trials in the region are also aiding the industry growth. The Asia Pacific is expected to provide enhanced growth opportunities for the market expansion over the forecast period owing to the presence of a large population and improving healthcare facilities in the region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Myelofibrosis Treatment: Market Segmentation
Myelofibrosis (MF), a rare disease, is a type of blood disorder called myeloproliferative neoplasm. All myeloproliferative neoplasms are classed as blood cancers by the World Health Organisation (WHO). In people with myelofibrosis, the scar tissue builds up inside the bone marrow due to which blood cells do not develop properly. The condition causes extensive scarring in bone marrow, leading to severe anaemia that can cause weakness and fatigue. A normal blood test, along with bone marrow biopsy, can help diagnose myelofibrosis in a person.
Based on drug type, the market is divided into:
- Hydroxyurea
- Immunomodulators
- JAK Inhibitor
- Others
Based on treatment type, the industry can be segmented into:
- Blood Transfusion
- Chemotherapy
- Androgen Therapy
- Stem Cell/Bone Marrow Transplantation
- Others
The major end-use sectors of the product include:
- Hospitals
- Clinics
- Bone Marrow Transplant Centres
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing R&D Activities and New Drug Approvals to Augment the Growth of the Myelofibrosis Treatment Industry
The unmet needs of the patients suffering from myelofibrosis are pushing manufacturers to innovate new solutions. The growing investments in the research and development activities to develop a specific treatment for myelofibrosis is expected to bolster the growth of the industry in the forecast period. The rapid advancements in technology and the ongoing clinical trials are contributing to the industry growth. Other factors like improved reimbursement policies, favourable government initiatives, growing healthcare sector, busy lifestyle and changing dietary patterns, increase in smoking population, and growing incidence of genetic disorders are also contributing to the industry growth. However, limited awareness and high costs involved in treatment might hamper the growth of the industry in the coming years.
Key Industry Players in the Global Myelofibrosis Treatment Market
The report gives a detailed analysis of the following key players in the global myelofibrosis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Incyte Corporation
- Novartis AG
- Celgene Corporation
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by SegmentL:
|
| Breakup by Drug Type |
|
| Breakup by Treatment Type |
|
| Breakup by End Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Myelofibrosis Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Myelofibrosis Treatment Historical Market (2018-2023)
8.3 Global Myelofibrosis Treatment Market Forecast (2024-2032)
8.4 Global Myelofibrosis Treatment Market by Drug Type
8.4.1 Hydroxyurea
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Immunomodulators
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 JAK Inhibitor
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Others
8.5 Global Myelofibrosis Treatment Market by Treatment Type
8.5.1 Blood Transfusion
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Chemotherapy
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Androgen Therapy
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Stem Cell/Bone Marrow Transplantation
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Others
8.6 Global Myelofibrosis Treatment Market by End Use
8.6.1 Hospitals
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Clinics
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Bone Marrow Transplant Centers
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Others
8.7 Global Myelofibrosis Treatment Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Myelofibrosis Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Myelofibrosis Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Myelofibrosis Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Myelofibrosis Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Myelofibrosis Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Incyte Corporation
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Novartis AG
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Celgene Corporation
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Eli Lilly and Company
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Gilead Sciences, Inc.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Myelofibrosis Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Myelofibrosis Treatment Historical Market: Breakup by Drug Type (USD Billion), 2018-2023
3. Global Myelofibrosis Treatment Market Forecast: Breakup by Drug Type (USD Billion), 2024-2032
4. Global Myelofibrosis Treatment Historical Market: Breakup by Treatment Type (USD Billion), 2018-2023
5. Global Myelofibrosis Treatment Market Forecast: Breakup by Treatment Type (USD Billion), 2024-2032
6. Global Myelofibrosis Treatment Historical Market: Breakup by End Use (USD Billion), 2018-2023
7. Global Myelofibrosis Treatment Market Forecast: Breakup by End Use (USD Billion), 2024-2032
8. Global Myelofibrosis Treatment Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Myelofibrosis Treatment Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Myelofibrosis Treatment Market Structure
Key Questions Answered in the Report
The global myelofibrosis treatment market is being driven by the blood and bone marrow cancer treatment market, which is projected to grow at a CAGR of 7% between 2024 and 2032.
The major drivers of the industry, such as rising disposable incomes, increasing population, the easy availability of agents required for chemotherapy, the approval of Ruxolitinib (Jakafi) by the US Food and Drug Administration, implementation of favourable government initiatives, improving healthcare facilities, and the rising number of clinical trials, are expected to aid the market growth.
The key trends guiding the growth of the market include the rising investments in the research and development activities and rising advancements in technology.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drug types in the market are hydroxyurea, immunomodulators, and JAK inhibitor, among others.
The leading treatment types in the industry are blood transfusion, chemotherapy, androgen therapy, and stem cell/bone marrow transplantation, among others.
The significant end-use sectors in the market are hospitals, clinics, and bone marrow transplant centres, among others.
The major players in the industry are Incyte Corporation, Novartis AG, Celgene Corporation, Eli Lilly and Company, and Gilead Sciences, Inc., among others.
Analyst Review
The global myelofibrosis treatment market is being driven by the rising implementation of favourable government policies. The market is being aided by the global blood and bone marrow cancer treatment market, which is expected to grow at a CAGR of 7% between 2021 and 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By drug type, the market is segmented into hydroxyurea, immunomodulators, and JAK inhibitor, among others. On the basis of treatment type, the industry is divided into blood transfusion, chemotherapy, androgen therapy, and stem cell/bone marrow transplantation, among others. Based on end-uses, the market is categorised into hospitals, clinics, and bone marrow transplant centres, among others. The major regional markets for myelofibrosis treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Incyte Corporation, Novartis AG, Celgene Corporation, Eli Lilly and Company, and Gilead Sciences, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER